{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:18:01Z","timestamp":1791011881391,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/s00467-006-0204-5","type":"journal-article","created":{"date-parts":[[2006,8,9]],"date-time":"2006-08-09T14:26:48Z","timestamp":1155133608000},"page":"1434-1439","source":"Crossref","is-referenced-by-count":28,"title":["Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients"],"prefix":"10.1007","volume":"21","author":[{"given":"Wacharee","family":"Seeherunvong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obioma","family":"Nwobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn L.","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanthi","family":"Chandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gast\u00f3n","family":"Zilleruelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,10,1]]},"reference":[{"key":"204_CR1","first-page":"S1","volume":"46","author":"National Kidney Foundation","year":"2005","unstructured":"National Kidney Foundation (2005) K\/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46:S1\u2013S103","journal-title":"Am J Kidney Dis"},{"key":"204_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00467-004-1788-2","volume":"20","author":"I Salusky","year":"2005","unstructured":"Salusky I (2005) Are new Vitamin D analogues in renal disease superior to calcitriol? Pediatr Nephrol 20:393\u2013398","journal-title":"Pediatr Nephrol"},{"key":"204_CR3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2165\/00148581-200305110-00005","volume":"5","author":"CP Sanchez","year":"2003","unstructured":"Sanchez CP (2003) Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment. Pediatr Drugs 5:763\u2013776","journal-title":"Pediatr Drugs"},{"key":"204_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/ki.1987.176","volume":"32","author":"IB Salusky","year":"1987","unstructured":"Salusky IB, Fine RN, Kangarloo H, Gold R, Paunier L, Goodman WG, Brill JE, Gilli G, Slatopolsky E, Coburn JW (1987) \u201cHigh-dose\u201d calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 32:89\u201395","journal-title":"Kidney Int"},{"key":"204_CR5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1681\/ASN.V3121938","volume":"3","author":"R Mathias","year":"1993","unstructured":"Mathias R, Salusky I, Harman W, Paredes A, Emans J, Segre G, Goodman W (1993) Renal bone disease in pediatric and young adult patients on hemodialysis in a children\u2019s hospital. J Am Soc Nephrol 3:1938\u20131946","journal-title":"J Am Soc Nephrol"},{"key":"204_CR6","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","volume":"73","author":"E Slatopolsky","year":"1999","unstructured":"Slatopolsky E, Brown A, Dusso A (1999) Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73:S14\u2013S19","journal-title":"Kidney Int Suppl"},{"key":"204_CR7","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1053\/ajkd.2001.28113","volume":"38","author":"F Llach","year":"2001","unstructured":"Llach F, Velasquez Forero F (2001) Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 38:S20\u2013S33","journal-title":"Am J Kidney Dis"},{"key":"204_CR8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00467-004-1792-6","volume":"20","author":"L Greenbaum","year":"2005","unstructured":"Greenbaum L, Grenda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB (2005) Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol 20:622\u2013630","journal-title":"Pediatr Nephrol"},{"key":"204_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/BF00860951","volume":"9","author":"F Cano","year":"1995","unstructured":"Cano F, Delucchi A, Wolff E, Rodriguez E, Fuentes A (1995) Calcitriol oral pulse therapy in children with renal osteodystrophy. Pediatr Nephrol 9:606\u2013608","journal-title":"Pediatr Nephrol"},{"key":"204_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1056\/NEJM198908033210502","volume":"321","author":"DL Andress","year":"1989","unstructured":"Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ (1989) Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274\u2013279","journal-title":"N Engl J Med"},{"key":"204_CR11","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/ki.1994.223","volume":"45","author":"LD Quarles","year":"1994","unstructured":"Quarles LD, Yohay DA, Carroll BA, Spritzer CF, Minda SA, Bartholomay D, Lobaugh BA (1994) Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710\u20131721","journal-title":"Kidney Int"},{"key":"204_CR12","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/ki.1994.380","volume":"46","author":"WG Goodman","year":"1994","unstructured":"Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GB, Salusky IR (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160\u20131166","journal-title":"Kidney Int"},{"key":"204_CR13","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","volume":"9","author":"KJ Martin","year":"1998","unstructured":"Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J (1998) 19-nor-1-\u03b1-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427\u20131432","journal-title":"J Am Soc Nephrol"},{"key":"204_CR14","first-page":"315","volume":"56","author":"J Lindberg","year":"2001","unstructured":"Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C (2001) A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 56:315\u2013323","journal-title":"Clin Nephrol"},{"key":"204_CR15","unstructured":"Melnick JZ, Kommala D, Mattingly S, Amdahl M, Greenbaum WL (2004) Paricalcitol and calcitriol in treating SHPT children: a comparison of 2 studies. St. Louis, MO, GPRD, Abbott Laboratories, Abbott Park, IL; Pediatrics Medical College of Wisconsin, Milwaukee, WI [Abstract]. J Am Soc Nephrol SU-PO939"},{"issue":"5Suppl 5","key":"204_CR16","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","volume":"38","author":"F Llach","year":"2001","unstructured":"Llach F, Yudd M (2001) Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38(5Suppl 5):S45\u2013S50","journal-title":"Am J Kidney Dis"},{"key":"204_CR17","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1053\/ajkd.1998.v32.pm9808143","volume":"32","author":"F Llach","year":"1998","unstructured":"Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E (1998) Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 32:S48\u2013S54","journal-title":"Am J Kidney Dis"},{"key":"204_CR18","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M, Tacetta C, Batlle D (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483\u20131490","journal-title":"Kidney Int"},{"key":"204_CR19","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","volume":"40","author":"DW Coyne","year":"2002","unstructured":"Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E (2002) Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40:1283\u20131288","journal-title":"Am J Kidney Dis"},{"key":"204_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus M, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446\u2013456","journal-title":"N Engl J Med"},{"key":"204_CR21","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJM198706183162504","volume":"316","author":"AB Korkor","year":"1987","unstructured":"Korkor AB (1987) Reduced binding of 1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316:1573\u20131577","journal-title":"N Engl J Med"},{"key":"204_CR22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1172\/JCI116720","volume":"92","author":"N Fukuda","year":"1993","unstructured":"Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y (1993) Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436\u20131443","journal-title":"J Clin Invest"},{"key":"204_CR23","first-page":"2000","volume":"85","author":"T Carling","year":"2000","unstructured":"Carling T, Rastad J, Szabo E, Westin G, Akerstrom G (2000) Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 85:2000\u20132003","journal-title":"J Clin Endocrinol Metab"},{"key":"204_CR24","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1053\/ajkd.2001.28112","volume":"38","author":"KJ Martin","year":"2001","unstructured":"Martin KJ, Gonzalez E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F (2001) Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 38:S57\u2013S63","journal-title":"Am J Kidney Dis"},{"key":"204_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1046\/j.1523-1755.1998.00724.x","volume":"53","author":"D Kuizon","year":"1998","unstructured":"Kuizon D, Goodman W, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205\u2013211","journal-title":"Kidney Int"},{"key":"204_CR26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1681\/ASN.2003100878","volume":"16","author":"CP Sanchez","year":"2005","unstructured":"Sanchez CP, He YZ (2005) Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism. J Am Soc Nephrol 16:929\u2013938","journal-title":"J Am Soc Nephrol"},{"key":"204_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/ndt\/15.3.375","volume":"15","author":"M Paczyk-Tomaszewska","year":"2000","unstructured":"Paczyk-Tomaszewska M, Zi\u00f3kowska H, Debinski A, Sieniawska M (2000) Vitamin D metabolite requirements in dialysed children receiving recombinant human growth hormone. Nephrol Dial Transplant 15:375\u2013378","journal-title":"Nephrol Dial Transplant"},{"key":"204_CR28","unstructured":"US Government (2006) VISN 21 Criteria for non-formulary use of paricalcitol. US Department of Veterans Affairs, USA"},{"key":"204_CR29","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","volume":"19","author":"D Dobrez","year":"2004","unstructured":"Dobrez D, Mathes A, Amdahl M, Marx S, Melnick J, Sprague S (2004) Paricalcitol-treated patients experience improved hospitalization outcomes compared to calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19:1174\u20131181","journal-title":"Nephrol Dial Transplant"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-006-0204-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-006-0204-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-006-0204-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-006-0204-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T08:28:41Z","timestamp":1627720121000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-006-0204-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["204"],"URL":"https:\/\/doi.org\/10.1007\/s00467-006-0204-5","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}